Ralmitaront
Ralmitaront
Investigational antipsychotic drug
Ralmitaront (INN , USAN ; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing a clinical trial for the treatment negative symptoms in schizophrenia and schizoaffective disorder.[1][2][3] Another clinical trial targeting acute psychotic symptoms of schizophrenia has been terminated due to lack of efficacy.[4] It is a partial agonist of the TAAR1.[5] The medication is being developed by the pharmaceutical company Hoffmann-La Roche.[1] Ralmitaront had completed phase 1 clinical trials.[1][6]